Micoral's active ingredient, miconazole, is an antifungal agent generally considered relevant for addressing conditions presenting with systemic or localized discomfort caused by fungal or yeast infections. Its application is relevant across a therapeutic domain of common fungal infections, such as athlete's foot (tinea pedis), ringworm (tinea corporis), jock itch (tinea cruris), and tinea versicolor. The product's therapeutic function is applied in addressing these infectious processes, which contributes to easing the overall symptom load associated with these conditions.

“Micoral may assist with maintaining a sense of stability when symptoms become more noticeable, supporting the patient during difficult episodes by easing distress.”

This supportive relief is relevant for managing symptom clusters that create noticeable physiological strain, such as symptoms related to physical discomfort like itching, burning, and scaling. It contributes to improved comfort during symptomatic periods, especially when symptoms interfere with routine activities. The treatment is commonly used in scenarios requiring short-term symptomatic assistance.

Quick Fact: Relief for Physical Discomfort

Regulatory References

1. NIH MedlinePlus Drug Information on Miconazole Topical

Micoral (oral Ketoconazole) is a highly restricted medication. Official regulatory documents define eligibility based on specific exclusions and last-line use constraints, primarily for adults.

Populations For Whom Use Is Contraindicated

Absolute contraindications prohibit use in the following populations:

• Patients with acute or chronic liver disease.
• Individuals with known hypersensitivity to ketoconazole or any of its components.
• Women who are pregnant.
• Patients with congenital or documented acquired QTc prolongation (a specific cardiac rhythm abnormality).

Eligibility and Use Restrictions

Use is not recommended for women who are breastfeeding, as the drug is excreted into human milk. The medication is also not recommended for use in children and adolescents under 18 years for the treatment of systemic fungal infections, as safety and efficacy are not established in this age group.

For approved adult use, Micoral is restricted to treating specific endemic mycoses (systemic fungal infections) only when other effective antifungal therapies have failed or are not tolerated.

Interactions with other medicines and products

Micoral (miconazole) has documented interactions with several medicinal products and categories, primarily due to its ability to inhibit the metabolism of other drugs that are broken down by the Cytochrome P450-3A and Cytochrome P450-2C9 enzyme systems. This inhibition can lead to increased concentrations and effects of the co-administered medicines, necessitating specific regulatory constraints.

Official Interaction Restrictions

Contraindicated Combinations The use of Micoral is restricted and should not be used concurrently with certain medicines. This includes cisapride, trizolam, oral midazolam, mizolastine, quinidine, simvastatin, and lovastatin.

Required Monitoring For other interacting drugs, the official regulatory profile mandates specific monitoring procedures. When used alongside Oral Anticoagulants, the anticoagulant effect, typically measured by the International Normalized Ratio (INR), must be monitored and the dose titrated accordingly. Similarly, when co-administered with Phenytoin, the levels of Phenytoin in the body must be monitored to manage potential changes in exposure.

Other Documented Interactions

Micoral also interacts with the live oral typhoid vaccine, and simultaneous use must be avoided due to interference with the vaccine's effectiveness. Additionally, the drug may cause interference with certain laboratory tests, such as the reporting of false-positive results in assays for urine glucose or protein.

Micoral acts as an inhibitor of fungal P450 14α-lanosterol demethylase, a key enzyme in the ergosterol biosynthesis pathway. Inhibition prevents the conversion of lanosterol into ergosterol, the main sterol required for fungal cell membrane integrity. This causes the accumulation of toxic methylated sterol precursors and results in a fragile, leaky, and functionally compromised cell membrane.

Simultaneously, Micoral modulates the fungus's defense systems by inhibiting antioxidant enzymes, including peroxidase and catalase. This interference promotes the accumulation of reactive oxygen species (ROS), causing widespread oxidative damage to vital intracellular components. This dual action—membrane disruption and oxidative damage—constitutes a mechanism that drives fungal cell apoptosis (programmed cell death).

Additionally, the disruption of the sterol pathway leads to the accumulation of farnesol, a signaling molecule that suppresses the fungal transition from the yeast form to the filamentous (mycelial) form. This suppression influences the pathogen's capacity for tissue invasion.

Micoral administration is governed by the specific pharmaceutical form, differentiating between systemic oral use and localized topical use. The official instructions define the precise route and procedural constraints required for proper administration.

Oral Dosing and Intake Conditions

The active ingredient, Ketoconazole, is administered orally as 200 mg tablets once daily for adult patients when treating specific systemic fungal infections. The dose may be increased to a maximum of 400 mg once daily. For optimal absorption, oral tablets must be taken with food. Due to its dependency on gastric acid, the tablets require a mandated timing separation from acid-reducing medications; intake should occur at least 2 hours before or 1 hour after such agents. Pediatric oral dosing for children 2 years and older is weight-based, following a regimen of 3.3 to 6.6 mg/kg/day as a single dose. The customary duration of use for systemic treatment is approximately six months.

---

Topical Administration Patterns

Topical forms, including the 2% cream and 2% shampoo, are restricted to external use only. The cream is applied once or twice daily, depending on the localized infection being managed. For the shampoo, use involves applying it, creating a lather, and ensuring a 3 to 5 minute contact time on the affected area before rinsing, with frequency ranging from a single application for treatment to twice weekly for maintenance patterns.

The research evidence for Micoral's active ingredient, Ketoconazole, is derived from various clinical studies evaluated by regulatory bodies. This overview describes the research conducted and what remains uncertain, focusing strictly on study findings without offering clinical advice.

Evidence for Topical Use in Skin and Scalp Infections

The evidence base for topical formulations (creams and shampoos) used for conditions like Tinea Versicolor and Seborrheic Dermatitis primarily consists of short-term Randomized Controlled Trials (RCTs). These trials explore short-term symptom changes, evaluating outcomes related to physical discomfort such as scaling and itching. Research describes that topical application was associated with reported measurements of symptom clearance and fungal elimination, the main outcomes studied. A notable limitation is that the evidence focuses almost entirely on short-term clearance. Since systemic absorption is minimal, the research provides limited information on long-term outcomes or recurrence rates over many months.

Evidence for Oral Use in Systemic Fungal Infections

The research for the oral tablet form, used for severe internal infections known as Endemic Mycoses, relies more on older, non-comparative clinical trials and long-term observational cohort studies. These explored outcomes related to systemic or functional imbalance in patients. Regulatory bodies note that while the compound was studied for this use, the evidence quality varies. Findings indicate that certainty remains low for this use. The oral formulation's use is often restricted, a decision reflecting the known limitations of the research, which includes modest sample sizes and studies that do not fully align with current standards.

Key Studies & References

1. Ketoconazole - NIH StatPearls
2. Ketoconazole 2% Shampoo: FDA Label (e.g., Nizoral)
3. Evidence-Based Review on the Management of Tinea Versicolor

Common questions about Micoral (FAQ)

Q: What if I forget to take a dose of Micoral?

A: Official instructions describe that if a dose is missed, it is generally advised that it be taken as soon as possible. However, if it is almost time for the next scheduled dose, the label suggests skipping the missed dose and resuming the regular schedule. Patients are consistently advised that they should not take a double dose to make up for the missed one.

Q: Are there any common foods or drinks that should be avoided when taking Micoral?

A: Official warnings state that the consumption of alcoholic beverages is discouraged during treatment due to the potential for an increased risk of liver damage. While the oral tablet is to be taken with food for optimal absorption, official labeling does not uniformly list specific common foods or non-alcoholic drinks to be restricted.

Q: Is it true that Micoral can affect how birth control pills work?

A: Micoral is described in official documents as affecting certain liver enzymes (Cytochrome P450-3A), which are involved in breaking down the hormones found in some oral contraceptives. This potential enzyme inhibition can change the concentration of the hormones in the body. Due to this potential interaction, regulatory bodies note that monitoring or dose adjustment of the co-administered drug may be necessary.

Q: Does Micoral cause weight gain or loss?

A: Weight changes are generally not listed among the most common side effects (occurring in 1–10% of users). However, official drug safety information reports anorexia (which may involve weight loss) and increased appetite among less frequently reported or rare effects.

Q: Is tiredness or fatigue a typical side effect of Micoral?

A: Official reports mention unusual tiredness or weakness as a symptom that can sometimes be associated with signs of a serious adverse effect, such as potential liver toxicity or adrenal insufficiency. Simple fatigue is also reported, though it is not typically categorized as a common reaction.

Q: Can Micoral cause mood changes or affect sleep?

A: Regulatory documents report that both insomnia (difficulty sleeping) and somnolence (unusual drowsiness) have been documented among less common effects. Changes in mood or mental status are noted as a type of serious adverse reaction that regulatory bodies advise reporting to a healthcare professional.

Q: Are there different forms of Micoral available, like liquid or capsules?

A: According to official regulatory labeling, the active ingredient in Micoral (ketoconazole) is available as oral tablets for systemic treatment, and as a cream or shampoo for topical (external) use. Liquid or capsule forms are not listed in the standard authorized dosage forms.

Q: Can Micoral be crushed or split if I have trouble swallowing pills?

A: Official product information generally does not include instructions for splitting or crushing the tablet form. Tablets are typically intended to be taken whole, and modification should be based on specific professional guidance. This is due to the requirements for proper absorption, which include taking the drug with food.

Q: Has Micoral been studied in children or teenagers?

A: The oral tablet form has a defined weight-based dose in its labeling for children 2 years and older. However, major regulatory bodies note that due to safety concerns, particularly the risk of liver toxicity, the use of oral Micoral in children and adolescents for systemic infections is generally not recommended.

Q: Does taking Micoral affect my ability to drive or operate machinery?

A: Official product information reports somnolence (drowsiness) or dizziness as possible adverse reactions. Patients who experience these effects after taking the medication are advised to exercise caution when engaging in activities such as driving or operating machinery.

Q: Are there any common interactions between Micoral and over-the-counter pain relievers?

A: Official drug interaction lists focus on prescription medications that are directly affected by Micoral. However, Micoral carries a risk of liver toxicity, and combining it with any other drug that also poses a risk to the liver (including certain OTC pain relievers) may increase that risk, which requires attention from a healthcare provider.

Q: How often do people have allergic reactions to Micoral?

A: Hypersensitivity (allergic reaction) is listed as an uncommon adverse reaction (occurring in 0.1% to 1% of users) for some formulations. More serious, life-threatening allergic reactions, such as anaphylaxis, are also reported in regulatory documents but are considered rare.

Q: Why would a doctor choose Micoral over other treatments for this condition?

A: Official documents define specific use constraints for oral Micoral. Due to the potential for serious side effects like liver damage, regulatory bodies state that the tablets should only be used to treat systemic fungal infections when other effective antifungal therapies have failed or are not tolerated.

Q: What should I do if a side effect feels severe?

A: Official guidance emphasizes the importance of seeking immediate professional medical attention for any severe symptoms. This is particularly crucial for signs of liver failure, severe allergic reaction, or serious heart rhythm problems.

Q: What happens if Micoral is used for longer than the prescribed time?

A: Regulatory guidance indicates that the medicine should be used exactly as directed by the prescriber. Using the drug beyond the recommended duration may potentially result in increased exposure levels and an elevated risk of serious adverse effects.

Q: Can I drink alcohol while I am using Micoral?

A: Official warnings state that the consumption of alcoholic beverages is discouraged during treatment. This advice is provided because combining alcohol with Micoral may potentially increase the risk of developing liver damage (hepatotoxicity).

Q: Are there any genetic factors that might affect how Micoral works for me?

A: Official regulatory descriptions explain that Micoral strongly affects certain liver enzymes (CYP450) that metabolize (break down) drugs. While not personalized advice, biological variation in these enzyme pathways can affect how a person processes the drug, which may influence its effects and interactions.

Micoral (Ketoconazole) must be stored at Controlled Room Temperature, which is defined by regulatory bodies as a temperature range of 20 C to 25 C (68 F to 77 F).

Storage Requirements

Official labeling mandates that the medication be protected from excess moisture and light. The product must be kept in its original container with the lid tightly closed to maintain product stability and prevent degradation. It is explicitly required to store Micoral out of the reach and sight of children to prevent accidental ingestion.

Disposal Instructions

Discard unused or expired Micoral by following official regulatory guidance. The preferred method is to take advantage of a drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance (e.g., used coffee grounds), sealed in a bag or container, and disposed of in the household trash, as directed by the FDA.